First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial.

Lee KH, Lee JS, Sugawara S, Kang JH, Kim HR, Inui N, Hida T, Yoshida T, Tanaka H, Yang CT, Inoue T, Nishio M, Ohe Y, Tamura T, Yamamoto N, Yu CJ, Akamatsu H, Takahashi S, Nakagawa K

Open source

DOI: 10.1016/j.lungcan.2025.108109
Published: 2025 Mar
Container: Lung cancer (Amsterdam, Netherlands)
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.lungcan.2025.108109,
  title = {First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial.},
  author = {Lee KH and Lee JS and Sugawara S and Kang JH and Kim HR and Inui N and Hida T and Yoshida T and Tanaka H and Yang CT and Inoue T and Nishio M and Ohe Y and Tamura T and Yamamoto N and Yu CJ and Akamatsu H and Takahashi S and Nakagawa K},
  year = {2025},
  journal = {Lung cancer (Amsterdam, Netherlands)},
  doi = {10.1016/j.lungcan.2025.108109},
  url = {https://doi.org/10.1016/j.lungcan.2025.108109}
}

RIS

TY  - JOUR
TI  - First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial.
AU  - Lee KH
AU  - Lee JS
AU  - Sugawara S
AU  - Kang JH
AU  - Kim HR
AU  - Inui N
AU  - Hida T
AU  - Yoshida T
AU  - Tanaka H
AU  - Yang CT
AU  - Inoue T
AU  - Nishio M
AU  - Ohe Y
AU  - Tamura T
AU  - Yamamoto N
AU  - Yu CJ
AU  - Akamatsu H
AU  - Takahashi S
AU  - Nakagawa K
PY  - 2025
JO  - Lung cancer (Amsterdam, Netherlands)
DO  - 10.1016/j.lungcan.2025.108109
UR  - https://doi.org/10.1016/j.lungcan.2025.108109
ER  -

APA

KH, L., JS, L., S, S., JH, K., HR, K., N, I., T, H., T, Y., H, T., CT, Y., T, I., M, N., Y, O., T, T., N, Y., CJ, Y., H, A., S, T., & K, N. (2025). First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial.. Lung cancer (Amsterdam, Netherlands). https://doi.org/10.1016/j.lungcan.2025.108109

Source records

pubmed · retrieved 2026-09-25T14:59:15.744Z
europe-pmc · retrieved 2026-09-25T14:59:15.755Z